



Important EAP Updates for PsA (Most Recent First):

- **EAP is no longer covering infliximab (Remicade) for any new PsA requests; only previously EAP funded patients will continue to receive coverage (this means that patients that received Remicade through private insurance or through a clinical trial will be ineligible for EAP funding).**
- **Section 4A – this area is to be completed only on the initial request; for RA and PsA, if there are less than 5 swollen joints at the time of initial request, patient can still be considered for funding but the location of the swollen joints must be provided.**
- **Section 4B – this area is to be completed when applying for renewal of funding. Rituximab renewals require additional information (provide original swollen joint count pre-infusion, previous infusion date – use the date of their Day 15 infusion, swollen joint count at 3 – 4 months after infusion and current swollen joint count).**
- **There has been a change from MOH re PsA and past DMARD therapy: now the funding criteria states that Methotrexate and EITHER leflunomide OR sulfasalazine must have been tried for at least 3 months.**